ImmuneBio targets an early February 2027 UK application for Ebstracell, with potential approval by the middle of the year, and says cash will fund operations through Q3 2027.
INMB · Inmune Bio, Inc. · Documents
Substantial doubt about the company's ability to continue as a going concern.
“These conditions and events raise substantial doubt about the Company’s ability to continue as a going concern. As a result, the Company has concluded that management’s plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern.”View the 10-Q filed Nov 5, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
INmune Bio plans to file CORDStrom’s UK Marketing Authorization Application during February 2027 and an FDA Biologics License Application at mid-2027. It reported a $11.4 million nine-month net loss, $16.3 million cash, and substantial doubt about continuing as a going concern.
Inmune Bio agreed to sell 3,000,000 shares at $1.50 per share and issue unregistered warrants for up to 3,000,000 additional shares, generating expected aggregate gross proceeds of $4.5 million before fees and expenses.
INmune Bio submitted its final pre-Marketing Authorisation Application package to the UK MHRA for Ebstrocel on October 20, 2026. The company targets a full MAA submission in early February 2027, with potential UK approval in mid-2027, subject to MHRA review. It also entered into a Master Services Agreement with Uniphar Durbin Ireland Limited and expects to submit a U.S. BLA in Q2 2027.